-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Suspension amplification culture of HEK293 cells in the production of viral vectors-Hand-by-step tutorial ★Breakthrough progress! The next generation of CAR-T cell therapy is expected to overcome the problem of solid tumorsMimiVac broke the news.
Click on the picture and sign up for the conference.
November 19, 2021/eMedClub News/--Recently, a clinical stage biotechnology company MimiVac LLC announced , SurVaxM received the US Food and Drug Administration (FDA) approval notice in the 2b trial phase to evaluate the effectiveness of the newly diagnosed glioblastoma
.
In August 2017, the US FDA granted the SurVaxM vaccine orphan drug title for the treatment of glioblastoma
.
SurVaxM is a peptide mimic tumor immune vaccine that can target a cell survival protein called Survivin.
It has a unique cell and antibody-mediated anti-tumor response, which can trigger T cell and B cell immunity and antibody-directed survivin pathway inhibition at the same time The dual mechanism of action stimulates the immune system to kill tumor cells containing survivin, controls tumor growth and prevents or delays tumor recurrence
.
Survivin protein is common in a variety of tumor types, and glioblastoma is the most common brain tumor in the adult population
.
At present, there are few clinical treatment options for patients with glioblastoma, mainly radiotherapy and chemotherapy
.
Usually only 25% of patients can survive for 1 year, and less than 5% of patients survive for more than 5 years
.
In addition to glioblastoma, there are also lung cancer, rectal cancer, liver cancer, gastric cancer and so on
.
This pan-expression feature indicates that through Survivin protein expression, there may be a wide range of anti-tumor effects
.
The SURVIVE trial is a randomized, blinded, placebo-controlled, multi-center study.
It mainly evaluates the overall survival rate of SurVaxM's main goals and endpoints.
Other goals will evaluate the molecular predictors of response, including MGMT methylation status, IDH1 Mutations and survivin specifically react
.
At present, MimiVac is using SurVaxM combined with other drugs to treat multiple indications, SurVaxM combined with Revlimid (BMS) to treat multiple myeloma; SurVaxM combined with Keytruda (Merck) (completely enrolled) to treat recurrent glioblastoma, etc.
.
Tumor vaccines In the past 30 years, people have conducted extensive research on tumor vaccines in animal models and humans, involving many different types of cancer
.
Tumor vaccines activate the body's own immune system and use tumor cells or tumor antigens to induce the body's specific cellular immunity and humoral immune response to achieve the purpose of eliminating or controlling tumors
.
These include peptides, mRNA, DNA, and dendritic cells (DC) and other simple drug forms
.
Moreover, with the continuous in-depth research on tumor vaccines, not only many gratifying results have been achieved, but also a variety of new tumor vaccine delivery systems have emerged, including liposomes, amphipathic vaccines, lipid complexes, and self-assembled nanoparticles.
.
mRNA tumor vaccine: ➤ In July 2021, Sunshine Biopharma announced that it has successfully used mRNA vaccine technology to inhibit the activity of the transcription factor NRF2.
This inhibition will improve the performance of anti-cancer drugs, thereby providing cancer patients with a better overall treatment effect
.
Sunshine Biopharma used NRF2 small molecule inhibitors and anti-cancer drugs for testing and research, and the results showed that NRF2 inhibited the latter anti-cancer drug (etoposide) by approximately 4 times
.
➤ In October 2021, NeoCura, a Chinese company based on artificial intelligence-based RNA precision medicine, and a Korean company based on an extracellular vesicle (EV) drug delivery platform, MDimune Inc, reached a cooperation agreement to jointly develop a cancer vaccine delivery system based on exosomes.
mRNA treatment
.
➤ In June 2021, BioNTech (NASDAQ: BNTX) recently announced that its therapeutic cancer vaccine candidate BNT111 has launched a phase 2 clinical trial of BNT111-01 for advanced melanoma
.
BNT111 is a therapeutic mRNA cancer vaccine administered intravenously, which encodes 4 tumor-associated antigens (TAA), namely NY-ESO-1, MAGE-A3, tyrosinase and TPTE.
More than 90% of melanomas One of these 4 TAAs is expressed in patients
.
DNA tumor vaccine: ➤ In October 2021, according to overseas media reports, Genentech has obtained a global license for the neoantigen vaccine developed by Vaccibody
.
The Roche subsidiary will provide up-front and near-term payments of US$200 million to obtain Vaccibody's technology to overcome the limitations of cancer vaccines
.
The two companies are cooperating for multiple types of VB10.
NEO is a clinical stage drug candidate created by Vaccibody by identifying new tumor epitopes in specific patients
.
At the end of last year, Vaccibody found that the vaccine had a 50% response rate in a small trial for people with head and neck squamous cell carcinoma and other tumor types, and said it had solved the cancer vaccine problem
.
➤ In July 2021, Geneos Therapeutics, a subsidiary of Inovio Pharmaceuticals, announced yesterday that the company’s DNA-based personalized neoantigen targeted vaccine on the GT-EPIC platform has performed the first cancer patient treatment.
Patients with degenerative astrocytoma (a type of advanced brain cancer)
.
The vaccine targets 30 antigens, including all 27 tumor-specific neoantigens and 3 tumor antigens identified from the patient’s tumor
.
Long peptide vaccine: ➤ In January 2021, researchers from Dana-Farber Cancer Institute, Bhamham and Women's Hospital (BWH) and Broad Institute published a new study in Nature Medicine, melanin Four years after tumor patients received the personalized cancer vaccine NeoVax treatment, the immune response triggered by the vaccine still maintained a strong and effective cancer control effect
.
NeoVax is a long peptide vaccine that targets up to 20 personalized neoantigens in a patient, and works by targeting specific proteins on these tumor cells
.
Summary At present, vaccines are no longer limited to disease prevention in the traditional sense.
In addition to being preventive, vaccines can also be therapeutic.
Therapeutic vaccines are used to treat diseases or diseases by inducing specific immune responses in individuals with the disease.
The effect of preventing the deterioration of the disease
.
This therapeutic vaccine is a hot research direction in the field of oncology
.
We also expect more companies to achieve positive results in the field of cancer vaccines and bring hope of treatment to more patients
.
Reference materials: 1.
https:// -of-newly-diagnosed-glioblastoma-301423544.
html2.
https://
Click on the picture and sign up for the conference.
November 19, 2021/eMedClub News/--Recently, a clinical stage biotechnology company MimiVac LLC announced , SurVaxM received the US Food and Drug Administration (FDA) approval notice in the 2b trial phase to evaluate the effectiveness of the newly diagnosed glioblastoma
.
In August 2017, the US FDA granted the SurVaxM vaccine orphan drug title for the treatment of glioblastoma
.
SurVaxM is a peptide mimic tumor immune vaccine that can target a cell survival protein called Survivin.
It has a unique cell and antibody-mediated anti-tumor response, which can trigger T cell and B cell immunity and antibody-directed survivin pathway inhibition at the same time The dual mechanism of action stimulates the immune system to kill tumor cells containing survivin, controls tumor growth and prevents or delays tumor recurrence
.
Survivin protein is common in a variety of tumor types, and glioblastoma is the most common brain tumor in the adult population
.
At present, there are few clinical treatment options for patients with glioblastoma, mainly radiotherapy and chemotherapy
.
Usually only 25% of patients can survive for 1 year, and less than 5% of patients survive for more than 5 years
.
In addition to glioblastoma, there are also lung cancer, rectal cancer, liver cancer, gastric cancer and so on
.
This pan-expression feature indicates that through Survivin protein expression, there may be a wide range of anti-tumor effects
.
The SURVIVE trial is a randomized, blinded, placebo-controlled, multi-center study.
It mainly evaluates the overall survival rate of SurVaxM's main goals and endpoints.
Other goals will evaluate the molecular predictors of response, including MGMT methylation status, IDH1 Mutations and survivin specifically react
.
At present, MimiVac is using SurVaxM combined with other drugs to treat multiple indications, SurVaxM combined with Revlimid (BMS) to treat multiple myeloma; SurVaxM combined with Keytruda (Merck) (completely enrolled) to treat recurrent glioblastoma, etc.
.
Tumor vaccines In the past 30 years, people have conducted extensive research on tumor vaccines in animal models and humans, involving many different types of cancer
.
Tumor vaccines activate the body's own immune system and use tumor cells or tumor antigens to induce the body's specific cellular immunity and humoral immune response to achieve the purpose of eliminating or controlling tumors
.
These include peptides, mRNA, DNA, and dendritic cells (DC) and other simple drug forms
.
Moreover, with the continuous in-depth research on tumor vaccines, not only many gratifying results have been achieved, but also a variety of new tumor vaccine delivery systems have emerged, including liposomes, amphipathic vaccines, lipid complexes, and self-assembled nanoparticles.
.
mRNA tumor vaccine: ➤ In July 2021, Sunshine Biopharma announced that it has successfully used mRNA vaccine technology to inhibit the activity of the transcription factor NRF2.
This inhibition will improve the performance of anti-cancer drugs, thereby providing cancer patients with a better overall treatment effect
.
Sunshine Biopharma used NRF2 small molecule inhibitors and anti-cancer drugs for testing and research, and the results showed that NRF2 inhibited the latter anti-cancer drug (etoposide) by approximately 4 times
.
➤ In October 2021, NeoCura, a Chinese company based on artificial intelligence-based RNA precision medicine, and a Korean company based on an extracellular vesicle (EV) drug delivery platform, MDimune Inc, reached a cooperation agreement to jointly develop a cancer vaccine delivery system based on exosomes.
mRNA treatment
.
➤ In June 2021, BioNTech (NASDAQ: BNTX) recently announced that its therapeutic cancer vaccine candidate BNT111 has launched a phase 2 clinical trial of BNT111-01 for advanced melanoma
.
BNT111 is a therapeutic mRNA cancer vaccine administered intravenously, which encodes 4 tumor-associated antigens (TAA), namely NY-ESO-1, MAGE-A3, tyrosinase and TPTE.
More than 90% of melanomas One of these 4 TAAs is expressed in patients
.
DNA tumor vaccine: ➤ In October 2021, according to overseas media reports, Genentech has obtained a global license for the neoantigen vaccine developed by Vaccibody
.
The Roche subsidiary will provide up-front and near-term payments of US$200 million to obtain Vaccibody's technology to overcome the limitations of cancer vaccines
.
The two companies are cooperating for multiple types of VB10.
NEO is a clinical stage drug candidate created by Vaccibody by identifying new tumor epitopes in specific patients
.
At the end of last year, Vaccibody found that the vaccine had a 50% response rate in a small trial for people with head and neck squamous cell carcinoma and other tumor types, and said it had solved the cancer vaccine problem
.
➤ In July 2021, Geneos Therapeutics, a subsidiary of Inovio Pharmaceuticals, announced yesterday that the company’s DNA-based personalized neoantigen targeted vaccine on the GT-EPIC platform has performed the first cancer patient treatment.
Patients with degenerative astrocytoma (a type of advanced brain cancer)
.
The vaccine targets 30 antigens, including all 27 tumor-specific neoantigens and 3 tumor antigens identified from the patient’s tumor
.
Long peptide vaccine: ➤ In January 2021, researchers from Dana-Farber Cancer Institute, Bhamham and Women's Hospital (BWH) and Broad Institute published a new study in Nature Medicine, melanin Four years after tumor patients received the personalized cancer vaccine NeoVax treatment, the immune response triggered by the vaccine still maintained a strong and effective cancer control effect
.
NeoVax is a long peptide vaccine that targets up to 20 personalized neoantigens in a patient, and works by targeting specific proteins on these tumor cells
.
Summary At present, vaccines are no longer limited to disease prevention in the traditional sense.
In addition to being preventive, vaccines can also be therapeutic.
Therapeutic vaccines are used to treat diseases or diseases by inducing specific immune responses in individuals with the disease.
The effect of preventing the deterioration of the disease
.
This therapeutic vaccine is a hot research direction in the field of oncology
.
We also expect more companies to achieve positive results in the field of cancer vaccines and bring hope of treatment to more patients
.
Reference materials: 1.
https:// -of-newly-diagnosed-glioblastoma-301423544.
html2.
https://
